Drug intelligence / Profile preview

CHXM-001

Development stage: Preclinical
Lead developer: ChomiX Biotech
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

CHXM-001 is a small molecule radionuclide drug conjugate (RDC) being developed by ChomiX for the treatment of solid tumors. Leveraging ChomiX's proprietary chemoproteomics platform, the drug is designed to target a specific membrane protein expressed on tumor cells. The conjugate consists of a small molecule targeting moiety linked to a radionuclide payload, which delivers localized cytotoxic radiation directly to the tumor site. This targeted approach is intended to induce DNA damage and cell death in malignant tissues while sparing healthy surrounding cells. As of early 2024, CHXM-001 is in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on CHXM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHXM-001.

Explore the full profile